Mr Richard Collier
Richard trained as a lawyer, was admitted to the bars of New York and the District of Columbia and practiced law for 5 years. Following this he spent 23 years as an investment banker in London and New York specializing in mergers and acquisitions and was involved in some of the largest cross-border transactions of the period. He has been active as a trustee in the charity sector for the last 15 years. He was a Fellow and Chair of the Investment Committee of Balliol College, Oxford University. He also served as a non-executive director of OXIP, an investment fund managing assets for charities, university endowments and pension funds.
Mr John Wetherington
John serves nonprofit organizations specializing in health and education in the United States and globally. He has served in CFO and COO roles and specializes in turnaround situations and organizations undergoing rapid growth. He is active with nonprofit boards currently serving as Treasurer of an international humanitarian medical organization and as Trustee for an endowment. Prior to engagement in the nonprofit sector John worked in international finance serving clients in the United States, Asia, and Latin America. He is a CPA (Colorado) and holds and MBA and DBA.
Mr Oliver Kemp
I have been CEO of Prostate Cancer Research for 4 years now. I am privileged to work with a fantastic board, staff team and volunteers who help us fund and implement all our research. In my free time I am Chair of Health Poverty Action, an international development organization strengthening health services in areas such as nutrition, water, sanitation, immunization, and income generation. We have over 500 staff based in 20 countries. Prior to this I was the CEO of Build Africa, awarded the prize for the "Best International Charity in the UK" 2012, which directly supported over 400,000 people, an increase of over 500% in six years.
Mrs Michelle McGuinness
Michelle is a consultant to the biopharmaceutical industry where she helps start-ups and small companies navigate the regulatory waters related to drug approvals. Previously, she spent more than 20 years in senior Regulatory, Quality & Compliance roles for large pharmaceutical companies and consulting firms. She is a scientific advisor for CureCADASIL and volunteers for several animal rescues. In her free time, Michelle enjoys training and competing in triathlon, aquathlon and open water swimming events.
Mr Adam Schayowitz
Adam Schayowitz is the Vice President and Medicine Team Lead at Pfizer Oncology. He joined Pfizer in 2018 to lead the prostate cancer franchise, grounded in XTANDI (enzalutamide); and more recently became responsible for the Colorectal and Melanoma franchise based on the Array acquisition. Prior to joining Pfizer, Adam lead the development of Zejula (niraparib) at Tesaro, including the pivotal phase 3 ovarian cancer program as well as other global studies in breast cancer, lung cancer, and prostate cancer in collaboration with Janssen. Prior to Tesaro, Adam was on the Medical Affairs leadership team at Algeta, where he was responsible for scientific communications, publications, data generation and KOL engagement for the commercialization of Xofigo (Radium-223). Adam holds a PhD in prostate cancer drug development from the University of Maryland and an MBA from Johns Hopkins.
Dr Christopher Shepard
Dr. Christopher Shepard has focused his career on translational stage through definitive Phase 2 /pivotal drug development in metabolic disease and oncology. He has supported over $1.5bn in investments and transactions in biotechnology/pharma spanning research, drug program development, combination product development, clinical trial design, and personalized medicine and biomarkers. He has worked on programs at Genentech, Pfizer, Astellas, Celgene, Boehringer Ingelheim, and Merck. Most recently, he has been in the CEO and Founding-CEO role at venture-backed biotechnology companies in the portfolios of OrbiMed Advisors and Nest Bio Ventures.
Dr Suman Shirodkar
Dr. Suman Shirodkar, is a physician-scientist motivated by transformative science leading to significant patient benefit and commercially successful products. She has management consulting expertise, having led consulting engagements at McKinsey, and broad commercial experience in oncology, HIV and cardiovascular areas from previous roles at Pfizer and Novartis. She is now Chief Executive Officer at Cambridge Epigenetix Ltd. Suman has a Bachelor of Medicine & Bachelor of Surgery from the University of Bombay and competed a PhD in Virology at Harvard University.
Mrs Christina Renner-Thomas
A Senior Executive, Non-Executive Director and Board Advisor with more than 20 years’ experience for FTSE 100, US listed companies, the public sector and start-ups across the UK, Europe, APAC and Africa, and deep sector experience in pharmaceuticals and healthcare services. As an international MBA graduate and a qualified pharmacist who specialized in oncology, she brings a pragmatic customer and patient centric approach to commercialization of medicines in specialty care across the globe. With over 20 years experience in the pharmaceutical industry she has held senior roles in marketing, medical digital and brand analytics over an increasing number of geographies.
Christina describes herself as pragmatic, having a passion for simplifying problems to expedite solutions with a focus on integrity and authenticity. She volunteers with organizations furthering the cause of gender equity and explores maintaining health through complementary therapies. She loves travelling and experiencing different cultures.
Dr Catherine C Turkel, PharmD, PhD, MBA
Dr. Turkel is a patient-centric leader with more than 20 years’ experience as an executive in startup and mid-size Pharma/Biotech companies. She understands challenges companies face at various stages of evolution and growth. She was CEO & Founder of Nezee Therapeutics, served as President and R&D head for Novus Therapeutics, and served as Vice President & Global Development Team Leader at Allergan. Dr. Turkel has formulated registration and commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas. She is passionate about development of innovative new treatments for patients with unmet needs. She currently serves as an independent Board Director for Object Pharma, Inc (private firm) and Prostate Cancer Research, Inc (nonprofit), and Dean Advisor at Chapman University School of Pharmacy.